6,008 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 7,200 | 7,200 | - | - | Employee Stock Option (right to buy) | |
| Mark C. Schiller | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 7,200 | 7,200 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 24,500 | 24,500 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Mark C. Schiller | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 24,500 | 24,500 | - | - | Employee Stock Option (right to buy) | |
| Mark C. Schiller | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 02 Jul 2024 | 6,688 | 33,007 (0%) | 0% | 0.6 | 3,879 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Michael Mordwinkin Nicholas | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2024 | 275,000 | 275,000 | - | - | Employee Stock Option (right to buy) | |
| L. Marc Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2024 | 295,000 | 295,000 | - | - | Employee Stock Option (right to buy) | |
| Franklin M. Berger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 60,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 60,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 90,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 140,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 195,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 195,000 | 195,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 17,793 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 17,793 | 17,793 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 280,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 1,200,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 1,200,000 | 1,200,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 500,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 500,000 | 500,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 580,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 580,000 | 580,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 175,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 200,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 170,000 | 0 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 260,000 | 0 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 125,000 | 0 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 87,500 | 0 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 87,500 | 87,500 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 190,000 | 0 | - | - | Stock Option (right to buy) | |
| Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 170,000 | 170,000 | - | - | Stock Option (right to buy) | |
| Micki Klearman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 52,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Courtney Wallace | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Courtney Wallace | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 52,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Nicholas Michael Mordwinkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 185,000 | 185,000 | - | - | Employee Stock Option (right to buy) | |
| Nicholas Michael Mordwinkin | Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 185,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Nicholas Michael Mordwinkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 20 Jul 2023 | 48,950 | 431,348 (1%) | 0% | 0.9 | 44,055 | Common Stock |
| Christopher Kirk | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2023 | 48,950 | 74,411 | - | - | Employee Stock Option (right to buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 195,000 | 195,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 580,000 | 580,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 190,000 | 190,000 | - | - | Employee Stock Option (right to buy) | |
| Nicholas Michael Mordwinkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 185,000 | 185,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 27,000 | 55,721 | - | - | Employee Stock Option (Right to Buy) | |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 10 Nov 2022 | 27,000 | 393,904 (1%) | 0% | 0.9 | 24,300 | Common Stock |
| Nicholas Michael Mordwinkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 33,060 | 123,361 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 23 Jun 2022 | 33,060 | 381,484 (0%) | 0% | 0.9 | 29,754 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 18 Mar 2022 | 45,000 | 870,691 (2%) | 0% | 17 | 765,000 | Common Stock |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 14.77 per share. | 18 Mar 2022 | 20,000 | 890,691 (2%) | 0% | 14.8 | 295,400 | Common Stock |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 15.96 per share. | 18 Mar 2022 | 15,000 | 825,691 (2%) | 0% | 16.0 | 239,400 | Common Stock |
| Marc L. Belsky | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 500,000 | 500,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 170,000 | 170,000 | - | - | Employee Stock Option (right to buy) | |
| Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 03 Jan 2022 | 5,000 | 63,690 (0%) | 0% | 16.5 | 82,250 | Common Stock |
| Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 3,896 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.91 per share. | 03 Jan 2022 | 5,000 | 68,690 (0%) | 0% | 5.9 | 29,550 | Common Stock |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 7,700 | 82,721 | - | - | Employee Stock Option (Right to Buy) | |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 14 Dec 2021 | 7,700 | 366,904 (0%) | 0% | 0.9 | 6,930 | Common Stock |
| Courtney Wallace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.91 per share. | 21 Sep 2021 | 8,896 | 792,899 (2%) | 0% | 5.9 | 52,575 | Common Stock |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.63 per share. | 21 Sep 2021 | 8,896 | 801,795 (2%) | 0% | 7.6 | 67,876 | Common Stock |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.60 per share. | 21 Sep 2021 | 8,896 | 810,691 (2%) | 0% | 5.6 | 49,818 | Common Stock |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Michael G. Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Jason Dinges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Micki Klearman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Marc L. Belsky | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| Noreen Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 280,000 | 280,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 1,200,000 | 1,200,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 260,000 | 260,000 | - | - | Employee Stock Option (right to buy) | |
| Vassiliki Economides | SVP, Strategy & External Aff. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| Franklin M. Berger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Michael G. Kauffman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Garner | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Jason Dinges | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | None | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 11 Jun 2020 | 100,000 | 784,003 (2%) | 0% | 5.5 | 550,000 | Common Stock |
| Noreen Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| Franklin M. Berger | None | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 04 Feb 2020 | 120,846 | 684,003 (1%) | 0% | 2.6 | 314,200 | Common Stock |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 04 Feb 2020 | 15,384 | 15,384 (0%) | 0% | 2.6 | 39,998 | Common Stock |
| John Franklin Fowler | Director, CEO | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 04 Feb 2020 | 38,461 | 38,461 (0%) | 0% | 2.6 | 99,999 | Common Stock |
| Christopher Kirk | Director, President and CSO | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 04 Feb 2020 | 38,461 | 342,609 (0%) | 0% | 2.6 | 99,999 | Common Stock |
| Vassiliki Economides | SVP, Strategy & External Aff. | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 04 Feb 2020 | 5,769 | 7,570 (0%) | 0% | 2.6 | 14,999 | Common Stock |
| Marc L. Belsky | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2020 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2020 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2020 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Vassiliki Economides | SVP, Strategy & External Aff. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2020 | 62,500 | 62,500 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2019 | 50,000 | 106,421 | - | - | Employee Stock Option (Right to Buy) | |
| John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 19 Dec 2019 | 50,000 | 346,954 (0%) | 0% | 0.9 | 45,000 | Common Stock |
| Elizabeth Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 17,793 | 17,793 | - | - | Stock Option (right to buy) | |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 13 Nov 2019 | 800 | 2,000 (0%) | 0% | 2.8 | 2,207 | Common Stock |
| John Franklin Fowler | Director, CEO | Purchase of securities on an exchange or from another person at price $ 3.24 per share. | 10 Oct 2019 | 1,000 | 296,954 (0%) | 0% | 3.2 | 3,235 | Common Stock |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2019 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Vassiliki Economides | SVP, Strategy & External Aff. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2019 | 35,000 | 35,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 20 Aug 2019 | 200 | 1,200 (0%) | 0% | 4.4 | 884 | Common Stock |
| Vassiliki Economides | SVP, Strategy & External Aff. | Purchase of securities on an exchange or from another person at price $ 4.41 per share. | 20 Aug 2019 | 350 | 1,801 (0%) | 0% | 4.4 | 1,544 | Common Stock |
| John Franklin Fowler | Director, CEO | Purchase of securities on an exchange or from another person at price $ 4.66 per share. | 13 Aug 2019 | 2,000 | 295,954 (0%) | 0% | 4.7 | 9,310 | Common Stock |
| Christopher Kirk | Director, President and CSO | Purchase of securities on an exchange or from another person at price $ 4.61 per share. | 13 Aug 2019 | 5,000 | 302,934 (0%) | 0% | 4.6 | 23,040 | Common Stock |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 4.82 per share. | 09 Aug 2019 | 500 | 1,000 (0%) | 0% | 4.8 | 2,410 | Common Stock |
| John Franklin Fowler | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.01 per share. | 09 Aug 2019 | 750 | 293,954 (0%) | 0% | 5.0 | 3,761 | Common Stock |
| John Franklin Fowler | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.26 per share. | 09 Aug 2019 | 500 | 293,204 (0%) | 0% | 5.3 | 2,628 | Common Stock |
| Christopher Kirk | Director, President and CSO | Purchase of securities on an exchange or from another person at price $ 4.97 per share. | 09 Aug 2019 | 5,000 | 297,934 (0%) | 0% | 5.0 | 24,830 | Common Stock |
| Vassiliki Economides | SVP, Strategy & External Aff. | Purchase of securities on an exchange or from another person at price $ 4.96 per share. | 09 Aug 2019 | 1,020 | 1,451 (0%) | 0% | 5.0 | 5,057 | Common Stock |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 5.65 per share. | 25 Jul 2019 | 444 | 444 (0%) | 0% | 5.7 | 2,510 | Common Stock |
| Marc L. Belsky | CFO | Purchase of securities on an exchange or from another person at price $ 5.80 per share. | 25 Jul 2019 | 56 | 500 (0%) | 0% | 5.8 | 325 | Common Stock |
| Vassiliki Economides | SVP, Strategy & External Aff. | Purchase of securities on an exchange or from another person at price $ 5.82 per share. | 22 Jul 2019 | 431 | 431 (0%) | 0% | 5.8 | 2,509 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2019 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2019 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2019 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2019 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Jason Dinges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2019 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Vassiliki Economides | SVP, Strategy & External Aff. | Purchase of securities on an exchange or from another person at price $ 10.19 per share. | 30 May 2019 | 750 | 11,320 (0%) | 0% | 10.2 | 7,643 | Common Stock |
| Vassiliki Economides | SVP, Strategy & External Aff. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2019 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Marc L. Belsky | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2019 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2019 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2019 | 87,500 | 87,500 | - | - | Employee Stock Option (right to buy) | |
| Niti Goel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2019 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Arthur M. Pappas | Ten Percent Owner | 25 Jun 2018 | 23,894 | 0 | - | - | Series B Preferred Stock, par value $0.001 per share | ||
| Arthur M. Pappas | Ten Percent Owner | 25 Jun 2018 | 23,894 | 23,894 (0%) | 0% | 0 | Common Stock, par value $0.001 per share | ||
| Arthur M. Pappas | Ten Percent Owner | 25 Jun 2018 | 290,924 | 290,924 (1%) | 1% | 0 | Common Stock, par value $0.001 per share | ||
| Arthur M. Pappas | Ten Percent Owner | 25 Jun 2018 | 290,924 | 0 | - | - | Series B Preferred Stock, par value $0.001 per share | ||
| Franklin M. Berger | None | 25 Jun 2018 | 197,076 | 513,157 (2%) | 1% | 0 | Common Stock | ||
| Franklin M. Berger | None | 25 Jun 2018 | 262,907 | 316,081 (1%) | 1% | 0 | Common Stock | ||
| Franklin M. Berger | None | 25 Jun 2018 | 262,907 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Franklin M. Berger | None | 25 Jun 2018 | 197,076 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Franklin M. Berger | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 25 Jun 2018 | 50,000 | 563,157 (3%) | 0% | 15 | 750,000 | Common Stock |
| Jean-Pierre Sommadossi | None | 25 Jun 2018 | 35,258 | 0 | - | - | Series B Convertible Perferred Stock | ||
| Jean-Pierre Sommadossi | None | 25 Jun 2018 | 52,581 | 0 | - | - | Series A Convertible Perferred Stock | ||
| Jean-Pierre Sommadossi | None | 25 Jun 2018 | 52,581 | 143,182 (0%) | 0% | 0 | Common Stock | ||
| Jean-Pierre Sommadossi | None | 25 Jun 2018 | 35,258 | 178,440 (0%) | 0% | 0 | Common Stock | ||
| Michael G. Kauffman | None | 25 Jun 2018 | 10,516 | 63,690 (0%) | 0% | 0 | Common Stock | ||
| Michael G. Kauffman | None | 25 Jun 2018 | 10,516 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Thomas F. Steyer | Other | 25 Jun 2018 | 125,927 | 125,927 (0%) | 0% | 0 | Common Stock | ||
| Thomas F. Steyer | Other | 25 Jun 2018 | 210,326 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Thomas F. Steyer | Other | 25 Jun 2018 | 125,927 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Thomas F. Steyer | Other | 25 Jun 2018 | 210,326 | 210,326 (1%) | 1% | 0 | Common Stock | ||
| John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2018 | 88,967 | 88,967 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2018 | 26,690 | 26,690 | - | - | Employee Stock Option (Right to Buy) |